{"id":66062,"date":"2026-05-24T11:11:29","date_gmt":"2026-05-24T03:11:29","guid":{"rendered":"https:\/\/flcube.com\/?p=66062"},"modified":"2026-05-24T11:11:30","modified_gmt":"2026-05-24T03:11:30","slug":"3d-medicines-enrolls-first-patient-in-pivotal-phase-iii-trial-of-envafolimab-for-resectable-nsclc","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66062","title":{"rendered":"3D Medicines Enrolls First Patient in Pivotal Phase III Trial of Envafolimab for Resectable NSCLC"},"content":{"rendered":"\n

3D Medicines<\/strong> (HKG: 1244<\/a>) announced the enrollment of the first patient in a Phase III clinical trial<\/strong> evaluating envafolimab<\/strong> as a neoadjuvant\/adjuvant therapy<\/strong> for resectable Stage III non-small cell lung cancer (NSCLC)<\/strong>.<\/p>\n\n\n\n

Clinical Trial Overview<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Trial Phase<\/strong><\/td>Phase III<\/td><\/tr>
Design<\/strong><\/td>Randomized, double-blind, placebo-controlled, multicenter<\/td><\/tr>
Patient Population<\/strong><\/td>Approximately 390 patients with resectable Stage III NSCLC<\/td><\/tr>
Clinical Sites<\/strong><\/td>~60 sites across China<\/td><\/tr>
Primary Endpoints<\/strong><\/td>Event-free survival (EFS), major pathological response (MPR) rate, pathological complete response (pCR) rate<\/td><\/tr>
Treatment Arms<\/strong><\/td>Envafolimab + platinum-doublet chemotherapy vs. placebo + platinum-doublet chemotherapy<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Drug Profile & Development History<\/h2>\n\n\n\n